诺华地拉罗司如何购买？

Novartis AG is a leading multinational company in the global pharmaceutical and consumer healthcare industries. Manufactured by Novartis, Switzerland, it is suitable for the treatment of patients with thalassemia or other rare anemias.

The results of a single-arm, multi-center, prospective clinical study enrolling 64 AA patients with transfusion-related iron overload confirmed the effectiveness and safety of Enrig (deferasirox) in reducing patients' ferritin levels. A prospective, observational study in my country using liver, pancreas, and heart as monitoring indicators confirmed that Enrig can improve organ function in patients with iron overload. The results of the TELESTO study released at the ASH 2018 meeting also proved that Enrige continuously reduces serum ferritin levels, while reducing the risk of heart function damage, liver function damage, transformation to leukemia and other events by 36.4%.

Tests have shown that Enrig (deferasirox) is easy to administer, can significantly reduce ferritin levels, and has a definite effect in protecting important target organ systems such as the liver, heart, and endocrine system. It is currently the preferred option for iron removal treatment.

How to buy Novartis deferasirox?

Novartis is currently on the market in China. To purchase Novartis deferasirox, patients need to consult and purchase it at major domestic hospitals or pharmacies with a prescription issued by a doctor. Novartis deferasirox, which is launched in China, is an original drug and the price is relatively high. Medical Travel has learned that the price of Novartis deferasirox listed abroad is much cheaper than in China. Patients can go abroad for medical treatment and buy the medicine with a prescription or contact domestic overseas medical service institutions to purchase it through direct mail. Medical Companion Travel is an overseas medical service company. Patients can consult the Medical Companion Travel Service for specific drug prices and purchase information.

Recommended related hot articles: /newsDetail/88622.html